Sanofi and Eurapharma sign strategic partnership in Morocco
The agreement aims to grow Maphar’s business in Morocco and other African markets
Casablanca, Morocco - 1 June 2017 – Sanofi, a key player in the Moroccan pharmaceutical industry, and Eurapharma, a CFAO Group subsidiary specialising in the production and distribution of medicines in Africa, have signed a partnership agreement designed to accelerate Maphar business development in Morocco and other African markets.
The agreement will come into effect in June 2017, with Eurapharma taking a majority (51%) stake in Maphar. There will also be closer cooperation between Eurapharma, Sanofi Morocco and Maphar, backed by a major business development plan for Morocco and other African markets. Sanofi will remain a key Maphar shareholder (49%) and will strengthen its leading position in the Moroccan pharmaceutical market through its subsidiary Sanofi-Aventis Maroc, which has made significant investments in industry, logistics and science over the past few years.
Maphar draws on nearly 65 years' experience as a comprehensive service provider, covering everything from registration and production to distribution and marketing of pharmaceuticals. The firm has earned the trust of more than 25 international laboratories whose products are available in the Moroccan market.
“The partnership with Eurapharma, a leader in pharmaceutical distribution in Africa, mirrors Maphar's strategy and drive to continue growing its business in Morocco while improving the quality of customer service in both production and distribution. This partnership strengthens Sanofi’s presence in Morocco by bringing in additional expertise,” said Amine Benabderrazik, General Manager of Sanofi Morocco.
For the past 60 years, Eurapharma has been a partner of choice for major pharmaceutical companies seeking to develop in Africa.
Jean-Marc Leccia, CEO of Eurapharma: “We are delighted to sign this partnership with Sanofi through Maphar, a leader in pharmaceutical production and distribution in Morocco. It dovetails with Eurapharma's strategic development in Africa. We will expand the Maphar customer portfolio in the Moroccan market and improve customer service while opening Maphar up to the African market, for which it already has a large range of products for export, such as Sanofi's antimalarial ASAQ.”
Sanofi-Aventis Maroc is a wholly-owned subsidiary of the Sanofi Group and a leader in the Moroccan pharmaceutical market. It will continue to develop its business in the country, strengthened by the partnership between Maphar and Eurapharma, and will focus on diabetes, cardiovascular disease, general medicine, rare diseases, vaccines and public health.
Credit photo: François Terrier
Go to top